Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Core Insights - Plus Therapeutics, Inc. has received an additional $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), part of a larger $17.6 million grant for its leptomeningeal cancer targeted radiotherapeutic development program [1][2] - The funding is expected to support the clinical development of REYOBIQ™ and the CNSide LM diagnostic test, with further funding anticipated over the next 12 months [2] Funding and Financial Support - The total grant from CPRIT is $17.6 million, with the recent $1.9 million being the second non-dilutive financing received, following a $1.6 million payment in July 2025 [1][2] - Plus Therapeutics is actively pursuing additional grant opportunities to enhance its capital position [2] Product Development - REYOBIQ™ is a novel injectable radiotherapy designed for targeted treatment of CNS tumors, with applications in recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer [4] - The ReSPECT-LM trial, which is part of the funding from CPRIT, focuses on dose optimization for leptomeningeal metastases [2][4] Market Context - Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer, with limited effective treatment options available, indicating a significant unmet medical need [3] - The median survival for patients with leptomeningeal metastases is typically between 2 to 6 months, underscoring the urgency for novel therapies [3] Institutional Support - CPRIT is recognized as the second-largest public cancer research funder globally, with a mission to invest in cancer research and prevention initiatives in Texas [5] - Plus Therapeutics benefits from additional support through active grants from the National Institutes of Health and the Department of Defense [2]